Vincerx Pharma

VINC

Biotechnology · Healthcare

Price

$0.01

+0.00 (+0.00%)

Market Cap

$66,475

Exchange

Other OTC

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+267.5% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 1.4M (2020) → 5.2M (2024)

Vincerx Pharma is a small clinical-stage biotechnology company focused on developing new cancer treatments. Its main work centers on experimental drugs designed to fight blood cancers and solid tumors, targeting patients who have few other options. The company does not yet sell any approved products and is entirely in the research and testing phase.

Vincerx makes no revenue from product sales. Instead, it funds its operations through equity offerings and other financing, which is typical for early-stage drug developers. The company is based in the United States and has a very small market footprint. Its biggest challenge is the high cost and uncertainty of clinical trials — most experimental drugs fail before reaching approval, and Vincerx must keep raising money to stay operational. Success depends almost entirely on whether its pipeline drugs can prove safe and effective enough to win regulatory approval and eventually reach patients.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+54.5% YoY

YoY Growth Rate

Strong earnings growth

R&D Spend

$15M/ year

↓ Declining (-45% vs prior year)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

9.3%ownership

Insiders own a meaningful stake in the company

Cash Runway

~3 months

$4M cash & investments

Short runway — potential dilution ahead through share issuance

Cash watch

Vincerx Pharma has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

Data not available

Operating Margin

N/A

Data not available

ROCE

-161.4%

Weak — -161.4% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-18.7%

Shrinking sales (-18.7% YoY)

EPS YoY

N/A

—

Data not available

EPS Consistency

8/8 quarters

Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

-2138.8%

Burning cash (-2138.8%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

Data not available

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

0.0x

Attractive valuation — P/E 0.0

P/E under 10. The price tag is small relative to last year's profit.

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial